-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $47

Benzinga·11/19/2025 10:12:12
Listen to the news
BTIG analyst Kambiz Yazdi initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $47.